Samsung Biologics (KS: 207940) has entered into a strategic partnership with fellow South Kora-based PharmAbcine for the development and manufacturing of oncology and neovascular candidate PMC-402.
South Korea-based Samsung will provide services from cell line development through to process development, cGMP clinical manufacturing and regulatory support.
PharmAbcine’s lead candidate olinvacimab is currently in Phase II clinical trials for a combination therapy to treat cancer with Merck & Co's (NYSE: MRK) Keytruda (pembrolizumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze